Discovery of a New Class of Synthetic Protein Kinase Inhibitors that Suppress Selective Aspects of Glial Activation and Protect Against β-Amyloid Induced Injury: A Foundation for Future Medicinal Chemistry Efforts Focused on Targeting Alzheimer's Disease Progression

Journal of Molecular Neuroscience

Volumn 20, Issue 3, 2003, Pages 411-423

  Watterson, D Martin ^a   Velentza, Anastasia V ^a   Zasadzki, Magdalena ^a   Craft, Jeffrey M ^a   Haiech, Jacques ^b   Van Eldik, Linda J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Alzheimer's disease; Cytokines; Drug discovery; Glia; Neuroinflammation; Protein kinase inhibitor; Pyridazines

Indexed keywords

AMYLOID BETA PROTEIN; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE; AUTACOID; ENZYME INHIBITOR; PROTEIN KINASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; FEASIBILITY STUDY; GENE CONTROL; GLIA CELL; INFLAMMATION; MOUSE; NEUROPROTECTION; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; ENCEPHALITIS; ENZYMOLOGY; GLIA; GLIOSIS; LONG EVANS RAT; MALE; METABOLISM; PATHOPHYSIOLOGY; RAT;

ANIMALIA;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CELLS, CULTURED; DRUG DESIGN; ENCEPHALITIS; ENZYME INHIBITORS; GLIOSIS; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; NEUROGLIA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIDAZINES; RATS; RATS, LONG-EVANS;

EID: 0642309498     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:20:3:411     Document Type: Article

References (38)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G. M., et al. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
2. Bezzi P. and Volterra A. (2001) A neuron-glia signalling network in the active brain. Curr. Opin. Neurobiol. 11, 387-394.
3. Cohen P. (2002) Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315.
4. Eddleston M. and Mucke L. (1993) Molecular profile of reactive astrocytes - implications for their role in neurologic disease. Neuroscience 54, 15-36.
5. Frautschy S.A., Yang F., Calderon L., and Cole G.M. (1996) Rodent models of Alzheimer's disease: rat Aβ infusion approaches to amyloid deposits. Neurobiol. Aging 17, 311-321.
6. Hauss-Wegrzyniak B. and Wenk G. L. (2002) Beta-amyloid deposition in the brains of rats chronically infused with thiorphan or lipopolysaccharide: the role of ascorbic acid in the vehicle. Neurosci. Lett. 322, 75-78.
7. Hauss-Wegrzyniak B., Lynch M. A., Vraniak P. D., and Wenk G. L. (2002) Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses. Exp. Neurol. 176, 336-341.
8. Hauss-Wegrzyniak B., Vraniak P., and Wenk G. L. (1999) The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol. Aging 20, 305-313.
9. Jantzen P. T., Connor K. E., DiCarlo G., Wenk, G. L., Wallace J. L., Rojani A. M., et al. (2002) Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22, 2246-2254.
10. Kettenmann H. and Ransom B. R., eds. (1995) Neuroglia. Oxford University Press, NY.
11. Knockaert M., Lenormand P., Gray N., Schultz P., Pouyssegur J., and Laurent M. (2002) p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene 21, 6413-6424.
12. Koistinaho M., Kettunen M. I., Goldsteins G., Keinanen R., Salminen A., Ort M., Bures J., et al. (2002) β-Amyloid precursor protein transgenic mice that harbor diffuse Aβ deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc. Natl. Acad. Sci. U.S.A. 99, 1610-1615.
13. 2 acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells. Brain Res. 867, 115-121.
14. Kumar C. C. and Madison V. (2001) Drugs targeted against protein kinases. Expert Opin. Emerging Drugs 6, 303-315.
15. Lim G. P., Yang F., Chu T., Chen P., Beech W., Teter B., et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714.
16. Lim G. P., Yang F., Chu T., Gahtan E., Ubeda O., Beech W., et al. (2001a) Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. 22, 983-991.
17. Lim G. P., Chu T., Yang F., Beech W., Frautschy S. A., and Cole G. M. (2001b) The curry spice curcumin reduces oxidative damage and amyloid pathology in Alzheimer transgenic mouse. J. Neurosci. 21, 8370-8377.
18. Lukas T. J., Mirzoeva S., Slomczynska U., and Watterson D. M. (1999) Identification of protein kinase inhibitors using combinatorial peptide chemistry based on functional genomics knowledge. J. Med. Chem. 42, 910-919.
19. McGeer P. L. and McGeer E. G. (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22, 799-809.
20. Mirzoeva S., Koppal T., Petrova T. V., Lukas T. J., Watterson D. M., and Van Eldik L. J. (1999) Screening in a cell based assay for inhibitors of microglial nitric oxide production reveals calmodulin regulated protein kinases as potential drug discovery targets. Brain Res. 844, 126-134.
21. Mirzoeva S., Sawker A., Zasadzki M., Guo L., Velentza A. V., Dunlap V., et al. (2002) Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic anti-neuroinflammatory compound. J. Med. Chem. 45, 563-566.
22. Moran M. A. and Gomez-Ramos P. (1998) Glial changes in aging and Alzheimer's disease, in Understanding Glial Cells, Castellano B., Gonzalez B., and Nieto-Sampedro M., eds., Kluiwer Academic Publishers, Boston, MA, pp. 385-404.
23. Perlman H., Pagliari L. J., Nguyen N., Bradley K., Liu H., and Pope R. M. (2001) The Fas-FasL death receptor and PI3K pathways independently regulate monocyte homeostasis. Eur. J. Immunol. 31, 2421-2430.
24. 2. Proc. Natl. Acad. Sci. U.S.A. 96, 4668-4673.
25. 2: differential effects on endotoxin-stimulated cytokine induction. J. Biol. Chem. 274, 28,823-28,827.
26. Popovich P. G., Guan Z., McGaughy V., Fisher L., Hickey W. F., and Basso D. M. (2002) The neuropathological and behavioral consequences of intraspinal microglial/ macrophage activation. J. Neuropathol. Exp. Neurol. 61, 623-633.
27. Qiao X., Cummins D. J., and Paul S. M. (2001) Neuro-inflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur. J. Neurosci. 14, 474-482.
28. Roberts L. J. and Morrow J. D. (2001) Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed., Hardman J. G. and Limbird L. E., eds., McGraw-Hill, NY, pp. 687-731.
29. Schumacher A. M., Velentza A. V., Watterson D. M., and Wainwright M. S. (2002) DAPK catalytic activity in the hippocampus increases during the recovery phase in an animal model of brain hypoxic-ischemic injury. Biochim. Biophys. Acta 1600, 128-137.
30. Van Eldik L. J. (2001) Glia and Alzheimer's disease. Neurochem. Intl. 39, 329-331.
31. Velentza A. V., Schumacher M., and Watterson D. M. (2002) Structure, activity, regulation, and inhibitor discovery for a protein kinase associated with apoptosis and neuronal death. Pharmacol. Ther. 93, 217-224.
32. Velentza A. V., Schumacher A. M., Weiss C., Egli M., and Watterson D.M. (2001) A protein kinase associated with apoptosis and tumor suppression: structure, activity and discovery of peptide substrates. J. Biol. Chem. 276, 38,956-38,965.
33. Virchow R. (1846) Über das granulierte Ansehen der Wandungen der Gerhirnventrikel. Allg. Z. Psychiatr. 3, 242.
34. Watterson D. M., Haiech J., and Van Eldik L. J (2002) Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses. J. Mol. Neurosci. 19, 89-94.
35. Watterson D. M., Mirzoeva S., Guo L., Whyte A., Bourguignon J.-J., Hibert M., et al. (2001) Ligand modulation of glial activation: cell permeable, small molecule inhibitors of serine-threonine protein kinases can block induction of interleukin-1 and nitric oxide synthase II. Neurochem. Int. 39, 459-468.
36. Weggen S., Eriksen J. L., Das P., Sagi S. A., Wang R., Pietrzik C. U., et al. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216.
37. Yan J. J., Cho J. Y., Kim H. S., Kim K. L., Jung J. S., Huh S. O., et al. (2001) Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Brit. J. Pharmacol. 133, 89-96.
38. Zandi P. P. and Breitner J. C. S. (2001) Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol. Aging 22, 811-817.